Patent ID: 11965896
Assignee: RENIBUS THERAPEUTICS, INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC G  A | IPC A  G

Claim 3:
4. A method of treating a patient determined to be at risk for future kidney injury comprising:
(a) performing an assay to determine the level of the cyclin-dependent kinase inhibitor p21 in the patient;
(b) performing an assay to determine the level of urinary albumin in the patient; and
(c) if the patient exhibits elevated levels of the cyclin-dependent kinase inhibitor p21 and albumin, treating the patient to reduce the risk of further kidney injury, wherein the treatment comprises one or more of administration of one or more steroids, ACE inhibitors, NRF2 activators, antioxidants, aldosterone antagonists, anti-inflammatory, anti-fibrotic, vasopressin antagonists, SGLT-2 inhibitors, immunosuppressive agents, organ protection with a combination of iron or iron sucrose and a heme protein degradation inhibitor, or acute kidney injury treatments, or the treatment comprises one or more of initiating renal replacement therapy, withdrawing delivery of compounds that are known to be damaging to the kidney, delaying or avoiding procedures that are known to be damaging to the kidney, and modifying diuretic administration, wherein the cyclin-dependent kinase inhibitor p21 is of SEQ ID NO. 1, wherein the patient has undergone a kidney transplant.